80 FR 79913 - Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration Federal Register Volume 80, Issue 246 (December 23, 2015)
Food and Drug Administration
Federal Register Volume 80, Issue 246 (December 23, 2015)
| Page Range | 79913-79915 | |
| FR Document | 2015-32250 |
[Federal Register Volume 80, Number 246 (Wednesday, December 23, 2015)] [Notices] [Pages 79913-79915] From the Federal Register Online [www.thefederalregister.org] [FR Doc No: 2015-32250] [[Page 79913]] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2015-D-1211] Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry; Availability AGENCY: Food and Drug Administration, HHS. ACTION: Notice. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing the availability of a document entitled ``Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry.'' The guidance document provides blood establishments that collect blood or blood components, including Source Plasma, with revised donor deferral recommendations for individuals at increased risk for transmitting human immunodeficiency virus (HIV) infection. The guidance document recommends corresponding revisions to donor educational materials, donor history questionnaires and accompanying materials, along with revisions to donor requalification, product management, and testing procedures. The guidance announced in this notice finalizes the draft guidance of the same title dated May 2015 and supersedes the memorandum to blood establishments entitled ``Revised Recommendations for the Prevention of Human Immunodeficiency Virus (HIV) Transmission by Blood and Blood Products'' dated April 23, 1992 (1992 blood memo). While this guidance represents FDA's current thinking on the subject, our recommendations may evolve over time as new scientific evidence becomes available. DATES: Submit either electronic or written comments on Agency guidances at any time. ADDRESSES: You may submit comments as follows: Electronic Submissions Submit electronic comments in the following way:Federal eRulemaking Portal: http://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to http://www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on http://www.regulations.gov. If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ``Written/Paper Submissions'' and ``Instructions''). Written/Paper Submissions Submit written/paper submissions as follows: Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ``Instructions.'' Instructions: All submissions received must include the Docket No. FDA-2015-D-1211 for ``Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry.'' Received comments will be placed in the docket and, except for those submitted as ``Confidential Submissions,'' publicly viewable at http://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. Confidential Submissions--To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION''. The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on http://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ``confidential.'' Any information marked as ``confidential'' will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to http://www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ``Search'' box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. Submit written requests for single copies of the guidance to the Office of Communication, Outreach, and Development, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993- 0002. Send one self-addressed adhesive label to assist the office in processing your requests. The guidance may also be obtained by mail by calling CBER at 1-800-835-4709 or 240-402-8010. See the SUPPLEMENTARY INFORMATION section for electronic access to the guidance document. FOR FURTHER INFORMATION CONTACT: Valerie A. Butler, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. SUPPLEMENTARY INFORMATION: I. Background FDA is announcing the availability of a document entitled, ``Revised Recommendations for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products; Guidance for Industry.'' The emergence of Acquired Immune Deficiency Syndrome (AIDS) in the early 1980s and the recognition that it could be transmitted by blood and blood products had profound effects on the [[Page 79914]] U.S. blood system. Although initially identified in men who have sex with men (MSM) and associated with male-to-male sexual contact, AIDS was soon noted to be potentially transmitted by transfusion of blood products, and by infusion of clotting factor concentrates in individuals with hemophilia. Beginning in 1983, FDA issued recommendations for providing donors with educational material on risk factors for AIDS and for deferring donors at increased risk for AIDS in an effort to prevent transmission of the agent responsible for AIDS (later understood to be caused by HIV) by blood and blood products. MSM (originally identified as gay or bisexual men) were deferred due to the strong clustering of AIDS illness among MSM and the subsequent discovery of high rates of HIV infection in that population. FDA's recommendation for deferral of MSM was modified over time to improve its clarity and to promote compliance, including a shift of focus from a deferral based on group identification to a deferral based on specific behavior (male sex with another male). Since September 1985, FDA has recommended that blood establishments indefinitely defer male donors who have had sex with another male, even one time, since 1977. On April 23, 1992, FDA issued the 1992 blood memo, which consolidated its recommendations regarding the deferral of donors at risk of HIV, including the deferral for MSM, as well as deferral recommendations for other persons with behaviors associated with high rates of HIV exposure, namely commercial sex workers, those who inject non-prescription drugs, and certain other individuals with HIV risk factors. The use of donor educational material, specific deferral questions, and advances in HIV donor testing have reduced the risk of HIV transmission from blood transfusion from about 1 in 2500 transfusions prior to HIV testing to a current estimated residual risk of about 1 in 1.47 million transfusions. Since the implementation in 1985 of donor testing for antibodies to HIV, FDA and the U.S. Department of Health and Human Services (HHS) have held a number of public meetings, including public scientific workshops and meetings of the Blood Products Advisory Committee and the HHS Advisory Committee on Blood Safety and Availability (ACBSA) to further review evidence and discuss FDA's blood donor deferral policies to reduce the risk of transmission of HIV by blood and blood products. Consistent with recommendations of the ACBSA in June 2010, studies that might support a policy change were carried out by the Public Health Service in 2011 to 2014. A recommendation for a policy change to the blood donor deferral period for MSM from indefinite deferral to 1 year since the last sexual contact was announced by the Commissioner of Food and Drugs in December 2014. This guidance implements that recommended policy change. In addition, the guidance provides donor deferral recommendations for other individuals at increased risk for transmitting HIV infection, including commercial sex workers, non-prescription injection drug users, women who have sex with MSM, and certain other individuals with other risk factors. The guidance provides revised recommendations for donor educational materials, donor history questionnaires and accompanying materials, as well as for donor requalification and product management procedures. In the Federal Register of May 15, 2015 (80 FR 27973), FDA announced the availability of the draft guidance of the same title dated May 2015. FDA received over 700 comments on the draft guidance and those comments were carefully considered as the guidance was finalized. Comments were received from a variety of organizations, including patient advocacy groups representing users of blood products; lesbian, gay, bisexual and transgender advocacy groups; medical and professional societies; academic institutions; human rights organizations; local governments; members of Congress; and, the blood industry. Comments were also received from hundreds of individual commenters. Approximately one-half of the comments opposed FDA's time-based deferral policy for MSM and considered the proposed policy to be discriminatory and lacking a scientific rationale. Many of these comments recommended that FDA adopt an individual risk assessment based approach, regardless of an individual's sexual orientation or gender identity. Other comments supported a time-based deferral policy shorter than 1year, or no deferral period at all, because of advances in blood donor testing technologies that permit earlier detection of new HIV infections. Comments requested that FDA commit to reexamining its deferral policies as new technologies, such as pathogen reduction technology are implemented and data regarding compliance with the revised policies become available. Most of the remaining comments advocated for the continuation of the indefinite deferral policy for MSM and expressed concern regarding the safety of the blood should the revised policy for MSM donors be adopted. Opponents of the proposed change commented on the HIV incidence and prevalence rates among MSM; the potential failure of HIV tests to capture window-period infections; the risk of emerging pathogens for which testing does not exist; and, the potential for decreased compliance rates with the new deferral policy. Other comments argued that FDA should not compromise public health and the safety of the blood supply to satisfy special interest groups. A smaller number of comments, including those from certain patient advocacy organizations, supported the proposed 1-year deferral policy for MSM predicated on the establishment of a transfusion-transmitted infectious disease monitoring system to enhance safety monitoring and allow rapid responses to emerging threats to the blood supply. Further, similar comments advocated for an evaluation of the effectiveness of the donor educational materials and donor history questionnaires prior to the implementation of new donor deferral policies. Finally, comments received from the blood industry were generally supportive of the revised MSM donor deferral policy. However, some comments noted that manufacturers of plasma for further manufacturing use (i.e., to make injectable products), including Source Plasma, collected in the United States and intended for further manufacturing use in other countries, may need to retain an indefinite deferral policy for MSM to comply with the indefinite deferral policies established in other countries. Industry commenters also requested revisions to certain other donor deferral criteria for HIV risk and disagreed with FDA's proposal to include the signs and symptoms associated with HIV infection in the donor educational materials. Comments requested clarification regarding the eligibility of donors with false-positive HIV tests and on recommendations for product retrieval and notification of consignees of distributed blood components collected from a donor who should have been deferred for HIV risk factors. Some comments were also supportive of the additional guidance provided by FDA regarding transgender donors. Finally numerous commenters requested FDA to clarify the recommendation for deferral of women who have had sex with MSM. FDA carefully considered all of the comments received in response to the draft guidance and the available scientific data, including the results of [[Page 79915]] recent studies conducted by the Public Health Service and revised the guidance accordingly. FDA considered several options to address the comments in response to the revised MSM donor deferral policy. Because evidence indicates that the indefinite deferral policy for MSM may have become less effective over time, FDA has determined that a change in policy is warranted at this time. Data on the limitations of nucleic acid tests to identify antibody negative window period HIV infections suggests that donor testing alone, absent any deferral for MSM, would result in an unacceptable increased risk of transfusion-transmitted HIV. Similarly, pretesting at risk donors with a rapid HIV test prior to donation would be logistically challenging and would not necessarily identify newly HIV-infected individuals. While individual donor assessment for risk has been implemented in a few countries, the implementation of this strategy in the United States would present significant practical challenges and currently there is no validated and accepted individual risk assessment tool or questionnaire. Therefore, FDA concluded a time-based deferral for history of male-male sex is the most appropriate policy to maintain the safety of the U.S. blood supply. Scientific data regarding the effectiveness of a 1-year deferral in Australia, a country with similar HIV epidemiology to the United States, supports FDA's policy change to the blood donor deferral period for MSM from indefinite deferral to 1 year since the last sexual contact. Scientifically robust data are not available for time-based deferrals of less than 1 year. FDA also concluded that scientific data are not currently available that would support revisions to the indefinite deferral policy for commercial sex workers or intravenous drug users. In response to comments, FDA made the following changes when finalizing the guidance: (1) Amended the recommendations regarding the inclusion of signs and symptoms associated with HIV in the donor educational materials; (2) revised the recommendation for the deferral of female donors who have had sex with MSM; (3) stated that FDA no longer recommends deferral for individuals who have had sex with an individual with hemophilia or related clotting deficiencies requiring treatment with clotting factor concentrates; and (4) revised the recommendations regarding product retrieval and consignee notification of distributed blood products collected from a donor who should have been deferred for HIV risk factors. In addition, FDA made the following changes to clarify certain recommendations in the guidance, which are consistent with current policy: (1) Clarified that donors who have been determined to have a false-positive HIV test may be reentered according to a requalification method found acceptable to FDA; (2) noted that recipients of allogeneic blood transfusions (i.e., not autologous transfusions), should be temporarily deferred; (3) provided reference to an FDA guidance on the collection of blood components from donors at risk of HIV infection; and (4) clarified the deferral by the responsible physician of a blood establishment of any donor if the donation could affect the health of the donor or the safety of the blood component. Additionally, the background section has been expanded to summarize FDA's evaluation of the available policy options under the available evidence relevant to the MSM deferral policy. Minor editorial changes have also been made to the guidance. FDA remains committed to exploring options and engaging in public discussions regarding enhancements to donor and public education regarding safe blood donors and evaluating the effectiveness of the donor history questionnaire. Further, with the implementation of a transfusion transmitted infectious disease monitoring system, FDA will be able to monitor donor risk factors and the safety of the blood supply, as well as investigate and refine blood safety measures in the future. FDA's recommendations may evolve over time as new scientific data become available on strategies to maintain or improve blood safety. The guidance announced in this notice finalizes the draft guidance dated May 2015 and supersedes the 1992 blood memo. This guidance is being issued consistent with FDA's good guidance practices regulation (21 CFR 10.115). The guidance represents the current thinking of FDA on recommendations for reducing the risk of HIV transmission by blood and blood products. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. II. Paperwork Reduction Act of 1995 The guidance refers to previously approved collections of information found in FDA regulations. These collections of information are subject to review by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-3520). The collections of information in 21 CFR 601.12 have been approved under OMB control number 0910-0338; the collections of information in 21 CFR 606.171 have been approved under OMB control number 0910-0458; and the collections of information in 21 CFR 610.46, 630.6, 640.3 and 640.63 have been approved under OMB control number 0910-0116. III. Electronic Access Persons with access to the Internet may obtain the guidance at either http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm or http://www.regulations.gov. Dated: December 17, 2015. Leslie Kux, Associate Commissioner for Policy. [FR Doc. 2015-32250 Filed 12-22-15; 8:45 am] BILLING CODE 4164-01-P
![Federal Register / Vol. 80, No. 246 / Wednesday, December 23, 2015 / Notices 79913
DEPARTMENT OF HEALTH AND solely responsible for ensuring that your for public viewing and posted on
HUMAN SERVICES comment does not include any http://www.regulations.gov. Submit
confidential information that you or a both copies to the Division of Dockets
Food and Drug Administration third party may not wish to be posted, Management. If you do not wish your
[Docket No. FDA–2015–D–1211] such as medical information, your or name and contact information to be
anyone else’s Social Security number, or made publicly available, you can
Revised Recommendations for confidential business information, such provide this information on the cover
Reducing the Risk of Human as a manufacturing process. Please note sheet and not in the body of your
Immunodeficiency Virus Transmission that if you include your name, contact comments and you must identify this
by Blood and Blood Products; information, or other information that information as ‘‘confidential.’’ Any
Guidance for Industry; Availability identifies you in the body of your information marked as ‘‘confidential’’
comments, that information will be will not be disclosed except in
AGENCY: Food and Drug Administration, posted on http://www.regulations.gov. accordance with 21 CFR 10.20 and other
HHS. • If you want to submit a comment applicable disclosure law. For more
ACTION: Notice. with confidential information that you information about FDA’s posting of
do not wish to be made available to the comments to public dockets, see 80 FR
SUMMARY: The Food and Drug
public, submit the comment as a 56469, September 18, 2015, or access
Administration (FDA or Agency) is
written/paper submission and in the the information at: http://www.fda.gov/
announcing the availability of a
manner detailed (see ‘‘Written/Paper regulatoryinformation/dockets/
document entitled ‘‘Revised
Submissions’’ and ‘‘Instructions’’). default.htm.
Recommendations for Reducing the Risk
of Human Immunodeficiency Virus Written/Paper Submissions Docket: For access to the docket to
Transmission by Blood and Blood read background documents or the
Submit written/paper submissions as electronic and written/paper comments
Products; Guidance for Industry.’’ The follows: received, go to http://
guidance document provides blood • Mail/Hand delivery/Courier (for
establishments that collect blood or www.regulations.gov and insert the
written/paper submissions): Division of
blood components, including Source docket number, found in brackets in the
Dockets Management (HFA–305), Food
Plasma, with revised donor deferral heading of this document, into the
and Drug Administration, 5630 Fishers
recommendations for individuals at ‘‘Search’’ box and follow the prompts
Lane, Rm. 1061, Rockville, MD 20852.
increased risk for transmitting human • For written/paper comments and/or go to the Division of Dockets
immunodeficiency virus (HIV) submitted to the Division of Dockets Management, 5630 Fishers Lane, Rm.
infection. The guidance document Management, FDA will post your 1061, Rockville, MD 20852.
recommends corresponding revisions to Submit written requests for single
comment, as well as any attachments,
donor educational materials, donor copies of the guidance to the Office of
except for information submitted,
history questionnaires and Communication, Outreach, and
marked and identified, as confidential,
accompanying materials, along with Development, Center for Biologics
if submitted as detailed in
revisions to donor requalification, Evaluation and Research (CBER), Food
‘‘Instructions.’’
product management, and testing Instructions: All submissions received and Drug Administration, 10903 New
procedures. The guidance announced in must include the Docket No. FDA– Hampshire Ave., Bldg. 71, Rm. 3128,
this notice finalizes the draft guidance 2015–D–1211 for ‘‘Revised Silver Spring, MD 20993–0002. Send
of the same title dated May 2015 and Recommendations for Reducing the Risk one self-addressed adhesive label to
supersedes the memorandum to blood of Human Immunodeficiency Virus assist the office in processing your
establishments entitled ‘‘Revised Transmission by Blood and Blood requests. The guidance may also be
Recommendations for the Prevention of Products; Guidance for Industry.’’ obtained by mail by calling CBER at 1–
Human Immunodeficiency Virus (HIV) Received comments will be placed in 800–835–4709 or 240–402–8010. See
Transmission by Blood and Blood the docket and, except for those the SUPPLEMENTARY INFORMATION section
Products’’ dated April 23, 1992 (1992 submitted as ‘‘Confidential for electronic access to the guidance
blood memo). While this guidance Submissions,’’ publicly viewable at document.
represents FDA’s current thinking on http://www.regulations.gov or at the FOR FURTHER INFORMATION CONTACT:
the subject, our recommendations may Division of Dockets Management Valerie A. Butler, Center for Biologics
evolve over time as new scientific between 9 a.m. and 4 p.m., Monday Evaluation and Research, Food and
evidence becomes available. through Friday. Drug Administration, 10903 New
DATES: Submit either electronic or • Confidential Submissions—To Hampshire Ave., Bldg. 71, Rm. 7301,
written comments on Agency guidances submit a comment with confidential Silver Spring, MD 20993–0002, 240–
at any time. information that you do not wish to be 402–7911.
ADDRESSES: You may submit comments made publicly available, submit your SUPPLEMENTARY INFORMATION:
as follows: comments only as a written/paper
submission. You should submit two I. Background
Electronic Submissions copies total. One copy will include the FDA is announcing the availability of
Submit electronic comments in the information you claim to be confidential a document entitled, ‘‘Revised
following way: with a heading or cover note that states Recommendations for Reducing the Risk
• Federal eRulemaking Portal: http:// ‘‘THIS DOCUMENT CONTAINS of Human Immunodeficiency Virus
tkelley on DSK3SPTVN1PROD with NOTICES
www.regulations.gov. Follow the CONFIDENTIAL INFORMATION’’. The Transmission by Blood and Blood
instructions for submitting comments. Agency will review this copy, including Products; Guidance for Industry.’’ The
Comments submitted electronically, the claimed confidential information, in emergence of Acquired Immune
including attachments, to http:// its consideration of comments. The Deficiency Syndrome (AIDS) in the
www.regulations.gov will be posted to second copy, which will have the early 1980s and the recognition that it
the docket unchanged. Because your claimed confidential information could be transmitted by blood and blood
comment will be made public, you are redacted/blacked out, will be available products had profound effects on the
VerDate Sep<11>2014 18:05 Dec 22, 2015 Jkt 238001 PO 00000 Frm 00097 Fmt 4703 Sfmt 4703 E:\FR\FM\23DEN1.SGM 23DEN1](https://thefederalregister.org/doc/80_FR_80159/page/1.svg)
![Federal Register / Vol. 80, No. 246 / Wednesday, December 23, 2015 / Notices 79915
recent studies conducted by the Public factors. In addition, FDA made the Budget (OMB) under the Paperwork
Health Service and revised the guidance following changes to clarify certain Reduction Act of 1995 (44 U.S.C. 3501–
accordingly. FDA considered several recommendations in the guidance, 3520). The collections of information in
options to address the comments in which are consistent with current 21 CFR 601.12 have been approved
response to the revised MSM donor policy: (1) Clarified that donors who under OMB control number 0910–0338;
deferral policy. Because evidence have been determined to have a false- the collections of information in 21 CFR
indicates that the indefinite deferral positive HIV test may be reentered 606.171 have been approved under
policy for MSM may have become less according to a requalification method OMB control number 0910–0458; and
effective over time, FDA has determined found acceptable to FDA; (2) noted that the collections of information in 21 CFR
that a change in policy is warranted at recipients of allogeneic blood 610.46, 630.6, 640.3 and 640.63 have
this time. Data on the limitations of transfusions (i.e., not autologous been approved under OMB control
nucleic acid tests to identify antibody transfusions), should be temporarily number 0910–0116.
negative window period HIV infections deferred; (3) provided reference to an
FDA guidance on the collection of blood III. Electronic Access
suggests that donor testing alone, absent
any deferral for MSM, would result in components from donors at risk of HIV Persons with access to the Internet
an unacceptable increased risk of infection; and (4) clarified the deferral may obtain the guidance at either
transfusion-transmitted HIV. Similarly, by the responsible physician of a blood http://www.fda.gov/BiologicsBlood
pretesting at risk donors with a rapid establishment of any donor if the Vaccines/GuidanceCompliance
HIV test prior to donation would be donation could affect the health of the RegulatoryInformation/Guidances/
logistically challenging and would not donor or the safety of the blood default.htm or http://
necessarily identify newly HIV-infected component. Additionally, the www.regulations.gov.
individuals. While individual donor background section has been expanded Dated: December 17, 2015.
assessment for risk has been to summarize FDA’s evaluation of the
Leslie Kux,
implemented in a few countries, the available policy options under the
available evidence relevant to the MSM Associate Commissioner for Policy.
implementation of this strategy in the
deferral policy. Minor editorial changes [FR Doc. 2015–32250 Filed 12–22–15; 8:45 am]
United States would present significant
practical challenges and currently there have also been made to the guidance. BILLING CODE 4164–01–P
is no validated and accepted individual FDA remains committed to exploring
risk assessment tool or questionnaire. options and engaging in public
discussions regarding enhancements to DEPARTMENT OF HEALTH AND
Therefore, FDA concluded a time-based HUMAN SERVICES
deferral for history of male-male sex is donor and public education regarding
the most appropriate policy to maintain safe blood donors and evaluating the
effectiveness of the donor history Health Resources and Services
the safety of the U.S. blood supply. Administration
Scientific data regarding the questionnaire. Further, with the
effectiveness of a 1-year deferral in implementation of a transfusion Agency Information Collection
Australia, a country with similar HIV transmitted infectious disease Activities: Proposed Collection; Public
epidemiology to the United States, monitoring system, FDA will be able to Comment Request
supports FDA’s policy change to the monitor donor risk factors and the safety
blood donor deferral period for MSM of the blood supply, as well as AGENCY: Health Resources and Services
from indefinite deferral to 1 year since investigate and refine blood safety Administration, HHS.
the last sexual contact. Scientifically measures in the future. FDA’s ACTION: Notice.
robust data are not available for time- recommendations may evolve over time
as new scientific data become available SUMMARY: In compliance with the
based deferrals of less than 1 year. FDA
on strategies to maintain or improve requirement for opportunity for public
also concluded that scientific data are
blood safety. comment on proposed data collection
not currently available that would
The guidance announced in this projects (Section 3506(c)(2)(A) of the
support revisions to the indefinite
notice finalizes the draft guidance dated Paperwork Reduction Act of 1995), the
deferral policy for commercial sex
May 2015 and supersedes the 1992 Health Resources and Services
workers or intravenous drug users.
blood memo. Administration (HRSA) announces
In response to comments, FDA made This guidance is being issued plans to submit an Information
the following changes when finalizing consistent with FDA’s good guidance Collection Request (ICR), described
the guidance: (1) Amended the practices regulation (21 CFR 10.115). below, to the Office of Management and
recommendations regarding the The guidance represents the current Budget (OMB). Prior to submitting the
inclusion of signs and symptoms thinking of FDA on recommendations ICR to OMB, HRSA seeks comments
associated with HIV in the donor for reducing the risk of HIV from the public regarding the burden
educational materials; (2) revised the transmission by blood and blood estimate, below, or any other aspect of
recommendation for the deferral of products. It does not establish any rights the ICR.
female donors who have had sex with for any person and is not binding on DATES: Comments on this ICR should be
MSM; (3) stated that FDA no longer FDA or the public. You can use an received no later than February 22,
recommends deferral for individuals alternative approach if it satisfies the 2016.
who have had sex with an individual requirements of the applicable statutes
with hemophilia or related clotting and regulations. ADDRESSES: Submit your comments to
paperwork@hrsa.gov or mail the HRSA
tkelley on DSK3SPTVN1PROD with NOTICES
deficiencies requiring treatment with
clotting factor concentrates; and (4) II. Paperwork Reduction Act of 1995 Information Collection Clearance
revised the recommendations regarding The guidance refers to previously Officer, Room 10C–16, 5600 Fishers
product retrieval and consignee approved collections of information Lane, Rockville, MD 20857.
notification of distributed blood found in FDA regulations. These FOR FURTHER INFORMATION CONTACT: To
products collected from a donor who collections of information are subject to request more information on the
should have been deferred for HIV risk review by the Office of Management and proposed project or to obtain a copy of
VerDate Sep<11>2014 18:05 Dec 22, 2015 Jkt 238001 PO 00000 Frm 00099 Fmt 4703 Sfmt 4703 E:\FR\FM\23DEN1.SGM 23DEN1](https://thefederalregister.org/doc/80_FR_80159/page/3.svg)
Document Created: 2018-03-02 09:21:02
Document Modified: 2018-03-02 09:21:02
| Category | Regulatory Information | |
| Collection | Federal Register | |
| sudoc Class | AE 2.7: GS 4.107: AE 2.106: | |
| Publisher | Office of the Federal Register, National Archives and Records Administration | |
| Section | Notices | |
| Action | Notice. | |
| Dates | Submit either electronic or written comments on Agency guidances at any time. | |
| Contact | Valerie A. Butler, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911. | |
| FR Citation | 80 FR 79913 |
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR